CD274 and cutaneous melanoma: Along similar lines, a recent study of the mutational landscape of metastases in patients with cutaneous melanoma refractory to BRAF inhibitors and ICB therapy [173] revealed that late mutational signatures were dominated by an accumulation of mutations in DNA repair pathways, as well as alterations affecting multiple immune-evasive processes (e.g., loss-of-function alterations in CDKN2A, B2M, JAK2, CD274/PD-L1, and PTEN), and associated with an immune desert TME [173].